Editorial Picks
Ten Questions to Ask Before Booking Stem Cell Therapy in Korea
An editorial checklist for the cosmopolitan traveller — what to ask the coordinator, the consulting physician, and oneself, before any signature is offered.
A pre-treatment question list is not, on first impression, the most glamorous artefact a Hong Kong reader brings into a Gangnam clinic — it is a folded sheet, a few items on a phone, perhaps a screenshot from an aunt who has done this before. 問清楚先做啦, my mother messaged when I told her I was researching this piece — ask everything first. She was, as ever, exactly right. The ten questions below are the ones I have come to recommend to friends asking how to prepare for a stem cell consultation in Seoul; they are not ranked, and the clinics worth one's afternoon will answer all of them without strain. The list is editorial rather than diagnostic. One reads, one asks, one listens to the cadence of the answer — and the appointment, edited this way, holds together.
How we built this list
The methodology behind a pre-treatment question list is, at its quietest, a form of editorial discipline — the slow assembly of items that consistently distinguish the clinic conversations that age well from the ones that do not. The questions on this page were drawn together from three quiet sources, none of them dramatic. The first is the published patient-facing material from the Korea Health Industry Development Institute and the Ministry of Health and Welfare, which set out the regulatory baseline that every Korean clinic operates within. The second is the U.S. Food and Drug Administration's consumer alert on regenerative medicine, which sets out — in plain language — the categorical claim patterns the careful reader should treat as red flags. The third is the conversational pattern one notices, after a few years of writing about this register, in the consultations that read undramatic on the day and continue to read undramatic six months later.
The list is curated rather than ranked. No question on the page is presented as more important than the others; the ten are meant to be asked together, in roughly the order they appear, across one or two consultations. None of them are designed to embarrass the clinic — the better Gangnam practices welcome the full set, answer them at the pace the patient sets, and provide the supporting documentation in writing where the answer references it. A clinic that resists the list, that compresses the answers, or that frames the questions themselves as a sign of insufficient trust is providing a useful signal of its own. The ten items, taken together, read as a conversation rather than an interrogation. The clinics worth one's afternoon recognise the difference.
#1 — What exactly is the cell preparation, and where does it come from?
The first question — and the one most often answered too quickly — is the procedural identity of the cells themselves. "Stem cell therapy" is a category, not a procedure description; the cosmopolitan reader is well advised to ask, plainly, whether the protocol on offer uses autologous cells (one's own tissue, harvested and processed during the visit) or allogeneic cells (donor-derived, from an established cell bank), and from which tissue source — adipose, bone marrow, umbilical cord, or another. The answer should arrive without circumlocution. A reasonable Gangnam clinic will name the source, the harvest method, the approximate cell yield expected from one's profile, and the regulatory category the preparation sits within under Korean medical law. 邊度嚟㗎啲細胞, a friend from Tatler Asia asked the coordinator on her own visit — where do the cells come from, exactly. The room slowed in a useful way.
The procedural granularity matters more than the marketing copy. A protocol described as "autologous adipose-derived stromal vascular fraction, harvested via 60ml lipoaspirate under local anaesthesia, processed in a closed system with no overnight culture, single-session injection" is the kind of description one wants. A protocol described as "premium stem cell rejuvenation" is not. The published literature on adipose-derived preparations is hedged but reasonably consistent on the broad safety profile of single-session, same-day-processed autologous protocols; the cosmopolitan reader does not need to memorise the literature to ask the question, only to listen for whether the clinic can answer in this register at all.
- Autologous or allogeneic — and which tissue source
- Same-day processing or cultured expansion
- Approximate cell yield expected for one's profile
- Regulatory category under Korean medical law
- Whether a written cell-preparation report is provided
#2 — Who is performing the procedure, and what is their licence record?
The second question is the one most patients assume has been answered before they walked into the lobby — and most often has not, in any verifiable form. The cosmopolitan reader is well within the standard of care to ask, plainly, which physician will perform the harvest and the injection, what their Korean medical licence number is, how long they have been practising in this specific protocol, and whether the consultation one is currently having is with the same person who will be present in the procedure room. The questions are not adversarial. They are the structural equivalent of asking a Mandarin Oriental concierge whether the suite one is being offered is the suite one is actually checking into.
The Korean medical licence regime is publicly searchable; the licence number is, in the better-drafted consent documents, printed on the first page beside the supervising physician's name. A reasonable clinic will offer this without prompting, and will note — in writing where appropriate — whether other staff (a dermatology fellow, a registered nurse, a clinic-specific cell-processing technician) are involved in any phase of the protocol. The published consumer guidance from KHIDI is consistent on this point: the patient is entitled to know, before signing, the identity and qualifications of every clinical hand involved in the procedure. A clinic that frames this as administrative is misreading the question. A clinic that prints the answer on the consent page is reading it correctly.
- Performing physician's full name and Korean licence number
- Years practising the specific protocol on offer
- Whether consulting and operating physician are the same person
- Other clinical staff involved in any phase
- Where the licence record can be verified independently
#3 — What does the published evidence actually say about this protocol?
The third question separates the clinics that have read the literature from the clinics that have read the marketing copy — and the cosmopolitan reader is the one best placed to ask it. The phrasing matters. One asks not for a guarantee of effect, but for the published evidence base the clinic is relying on for the protocol on offer: which peer-reviewed studies, which patient populations, which outcome measures, and what the realistic effect size is in the literature for someone of one's profile. The answer should arrive with hedging, not with categorical claims. A 2020 review published in Nature Reviews Drug Discovery, frequently cited in the contemporary mesenchymal stem cell literature, frames the field's evidence base as "promising but heterogeneous" — and a clinic comfortable with that exact phrase is signalling something the marketing brochure cannot.
The phrasing one wants to hear is hedged: "patients report," "may help," "studies suggest," "in a meaningful proportion of cases." The phrasing one does not want to hear is categorical: "will," "guarantees," "cures," "reverses." Studies suggest that consent disputes, the rare ones that reach formal review, often turn on the gap between the categorical promise patients report having heard and the hedged language the actual literature supports. The cosmopolitan reader's working test is whether the clinic, asked directly, will name the studies and the limitations in the same breath. If the limitations require a second prompt to surface, the protocol's evidence base has been presented to the patient incompletely — and the appropriate response is to ask, slowly, for the more honest version.
#4 — What are the risks, in descending order of frequency?
The fourth question is the one the consent form is meant to answer in writing, and the one a careful patient should still ask out loud. The phrasing is deliberate — risks in descending order of frequency, not risks one is reassured are uncommon. The published profile for autologous adipose-derived preparations, as set out in the regenerative medicine literature, is dominated by transient injection-site reactions, mild systemic flu-like symptoms, occasional headache, and rare allergic responses to the carrier solution; serious adverse events remain uncommon when cells are prepared in regulated facilities, but the word "uncommon" is doing real work, and the careful reader should ask the clinic to define it numerically where the data permits. Patients report, in the medical-tourism literature, that the clinics they trust most are the ones whose risk disclosure reads more like an annotated invoice than a marketing reassurance.
The disclosure threshold is itself worth understanding. The framework one encounters in most jurisdictions, and which Korean medical practice broadly tracks, is some variant of the "reasonable patient" standard — the document and the conversation must disclose risks that a reasonable patient would consider material in deciding whether to proceed. This is a higher standard than "risks the practitioner considers likely." The cosmopolitan reader's working test is whether one could, after the conversation, write a paragraph explaining the risk profile to a friend who asked whether to proceed. If the answer is no, the disclosure has been incomplete in a meaningful sense — and the appropriate response is, again, to ask for more, not to sign for less.
- Common — transient site reactions, mild fatigue, modest soreness
- Uncommon — flushing, transient headache, mild swelling
- Rare — allergic response to carrier solution, infection at site
- Very rare — serious immune reaction, ectopic tissue formation
- Procedure-specific risks listed by clinic protocol
#5 — What is the full pricing structure, and what is not included?
The fifth question is one of cost transparency, and it is more layered than it appears at first reading. The headline price quoted in the lobby brochure — the figure that brings the Hong Kong reader into the appointment — is, in the better-drafted clinic communications, only the procedure fee. The careful patient should ask for a written breakdown that includes the consultation, the laboratory cell-preparation fee, the harvest procedure if applicable, the injection session, anaesthesia (local or otherwise), post-procedure aftercare, follow-up appointments, any imaging or laboratory work pre- or post-procedure, and the medication taken home. The cost transparency on stem cell pricing in Gangnam — and our cost transparency notes covers the line items in detail — is itself a marker of editorial seriousness. A clinic that itemises in writing is not the more expensive clinic; it is the more honest one.
The currency framing matters too. A figure quoted in Korean won converts differently for a Hong Kong reader than for a Singaporean reader; the careful coordinator will offer the won figure first, the USD equivalent second, and will note explicitly that any future revision sessions, if recommended, are quoted separately. 咁總共幾多錢, my friend asked her coordinator — what is the total, all in. The answer arrived in three lines on letterhead, with a date and a signature, and read as the kind of document a Mandarin Oriental concierge would produce for a multi-night booking. That is the register one is looking for. A clinic that resists itemisation, or that quotes a single "package" figure that resists breakdown, is providing a different kind of signal entirely.
#6 — What does the consent document actually say, and may I read it in advance?
The sixth question is procedural and, in the better practices, almost embarrassingly easy to answer. The cosmopolitan reader is well within the conventional standard of care to ask whether the consent document can be reviewed in advance — by email, by overnight take-home from the consultation, or by appointment to read in the clinic's quiet room before the procedure day. A clinic that resists this request is producing the wrong kind of friction. A clinic that emails the document the same afternoon, in both Korean and a translation appropriate to the patient's first language, is producing the right kind. Reading the informed consent line by line covers the structure of the document itself; the question one is asking here is procedural rather than substantive — when, in what format, and with what time to read.
The substantive read should not be hurried. The document is the only place where the protocol, the risks, and the assumptions are set out in plain text, and the conversation in the consultation room cannot substitute for the careful overnight read on a hotel terrace with a glass of water and no further appointments. A clinic that frames the procedure as time-limited in a way that requires same-day signature is misreading the standard of care. A clinic that hands the document over with the gentle suggestion to take one's time with it is reading the standard correctly. 慢慢嚟睇啦, as my friend said when I described this piece — read it slowly, in other words. The document rewards the unhurried pass.
#7 — What is the realistic timeline for visible effect, and for revision?
The seventh question is one of patience, and one the marketing brochure is least equipped to answer truthfully. Stem cell protocols, in the contemporary aesthetic and regenerative literature, are characterised by gradual onset; the visible effect, where the protocol produces one, is typically reported across weeks rather than across days, and the published outcome curves are heterogeneous. The cosmopolitan reader is well advised to ask the clinic for the realistic timeline in their specific protocol — when the patient is likely to first notice change, when the apparent effect is expected to plateau, how long the effect, where established, has historically held in their patient cohort, and whether and when revision or supplementary sessions are typically recommended.
The answer should be hedged. "In a meaningful proportion of patients, modest visible effect is reported between four and twelve weeks, with the apparent plateau commonly noted around the third month — though individual variability is substantial" is the kind of answer one is looking for. "Results in two weeks" is not. The realistic-timeline question is the one that protects the reader's calendar and one's expectations in equal measure. Patients report, in the medical-tourism literature, that disappointment with stem cell outcomes most often correlates with timeline mismatch — the patient was promised a fortnight, not a season, and the actual published effect curves run on the season's clock. A clinic that holds the timeline at the season's register is a clinic with which one's expectations are aligned. The Hong Kong reader, trained on Causeway Bay's faster cadence, learns to recalibrate accordingly.
#8 — What is the aftercare protocol, and who is responsible for it?
The eighth question is one of continuity. A stem cell protocol does not end at the moment the injection is completed; the careful clinic provides a written aftercare document that sets out, in plain language, what the patient should do over the following hours, days, and weeks — hydration, activity restrictions, medications to avoid, signs that warrant a return to the clinic, follow-up appointment cadence, and the named individual responsible for fielding questions between appointments. The cosmopolitan reader is well within the standard of care to ask, plainly, who that named individual is, in what languages they respond, on what hours, and through which channel — telephone, WhatsApp, LINE, KakaoTalk, or email. A clinic that names a coordinator, prints the contact on letterhead, and notes the response-time expectation is providing the kind of continuity the protocol's outcome quietly depends on.
The aftercare protocol should travel home with the patient. The Hong Kong reader who returns to Causeway Bay the morning after the procedure is, by definition, not in the same city as the clinic for the most consequential weeks of the recovery curve; the document should be specific enough that one's GP at home — should one need to consult them — can read it and orient themselves without further reference. The published guidance on cross-border medical aftercare is consistent on this point: the stronger the written aftercare protocol, the better the patient is served when the inevitable mid-recovery question arrives at hour ten of a quiet evening at home. 返到屋企搵邊個, my mother asked — who do I call once I am back home. The answer should already be on the page one was handed at the door.
#9 — How do I verify the clinic's registration as a foreign patient facility?
The ninth question is one of regulatory orientation, and it is the one most often skipped by patients who assumed the question was already answered by the clinic's having a website. It was not. Korean medical clinics that lawfully treat foreign patients are required to hold a separate registration, distinct from the ordinary medical clinic licence — a foreign patient attraction registration, issued by the Ministry of Health and Welfare and administered through KHIDI's published register. The cosmopolitan reader is entitled to ask, plainly, whether the clinic holds this registration, what its registration number is, when it was issued and last renewed, and where the patient may verify the entry independently. The KHIDI English-language portal, alongside the Ministry's own public listings, is the authoritative source.
The question is not a test of trust; it is a structural confirmation. A clinic with a current registration will answer in a single sentence, often offering the registration number on a printed card or in the consent document. A clinic without one — or one whose registration has lapsed, been suspended, or been issued under a different operating entity — is in a different regulatory category, and the cosmopolitan reader's protections under Korean law differ accordingly. The published material from KHIDI is unambiguous on the patient-side benefits of the registration: dispute resolution, language support, complaint channels, and the regulatory backstop that a patient operating outside the registered framework simply does not have. One asks. One verifies. One proceeds, where the answer holds, and pauses, where it does not.
#10 — What are my rights if I change my mind, before, during, or after?
The tenth question is the one a careful reader saves for last, and the one the better clinics are most comfortable answering. The patient's right to withdraw consent — at any point before the procedure, at any reasonable point during preparation, and the patient's rights to redress after — is set out in the consent document, in the clinic's published patient charter, and in the regulatory framework KHIDI administers. The cosmopolitan reader is well within the standard of care to ask, plainly, what those rights are. May one cancel the morning of the procedure without forfeiting the full deposit? May one pause mid-consultation, without prejudice, and reschedule? If, after the procedure, the patient is dissatisfied with the outcome — or believes the procedure was not as described — what are the formal channels through which a complaint or a review can be raised, and within what window? 如果我改變主意呢, the most important question my friend ever asked her coordinator — what if I change my mind. The room slowed, in a useful way, again.
The answers should arrive in writing or, at minimum, be backed by a written reference one can take home. A clinic that narrates these rights with confidence — that volunteers the cancellation policy before being asked, that names the dispute resolution channel by name, that prints the relevant clause numbers in the consent document — is the clinic that has internalised the patient's position properly. A clinic that frames withdrawal of consent as a hypothetical inconvenience is one whose conversations have been organised around the wrong centre of gravity. The tenth question is the one the Hong Kong reader is least likely to feel comfortable asking; it is also the one whose answer most reliably distinguishes the appointments that age well from the ones that do not.
Comparison table — what each question is verifying
The ten questions are not interchangeable; each verifies a different layer of the clinic's editorial seriousness, and the table below sets the layers out at a glance for the reader who wants the structural map alongside the long-form notes above.
| Question | What it verifies | Documentary form | Red-flag signal |
|---|---|---|---|
| #1 Cell preparation | Procedural identity | Cell preparation report | Category-only description |
| #2 Performing physician | Operator identity | Licence number on consent | Different consultant and operator |
| #3 Published evidence | Clinic literacy | Cited studies on request | Categorical outcome claims |
| #4 Risk profile | Disclosure threshold | Itemised risk list | Single 'side effects may include' line |
| #5 Pricing structure | Cost transparency | Itemised letterhead quote | Single package figure |
| #6 Consent advance review | Procedural respect | Document delivered in advance | Same-day signature pressure |
| #7 Effect timeline | Outcome honesty | Hedged time band | Two-week visible result |
| #8 Aftercare protocol | Continuity of care | Written aftercare document | No named coordinator |
| #9 Foreign patient registration | Regulatory standing | Registration number on card | No KHIDI entry |
| #10 Patient rights | Withdrawal and redress | Written charter or clause | Hypothetical framing of withdrawal |
Editorial note
The list above is a reading aid, not a verdict. The clinics worth one's afternoon will answer the ten without strain, in writing where the answer is documentary, and at the pace the patient sets — and the reader who arrives at the consultation with the questions folded in a notebook is, in our editorial view, the reader who arrives prepared. The questions belong on the desk before the consent form does. 問清楚先做, as my mother put it on a long Causeway Bay phone call earlier this year — ask everything first, and then decide. The advice ages well.
“問清楚先做啦 — ask everything first, then decide.”
A Hong Kong reader's mother, on a long Causeway Bay phone call
Frequently asked questions
Should I bring all ten questions to the first consultation?
Yes — and a careful coordinator will not be surprised by them. The list reads naturally as a single conversation across one or two consultations; the better Gangnam clinics will work through the items in roughly the order they appear, and will offer to provide the documentary answers — licence number, registration number, cell preparation report, itemised quote — in writing on letterhead. A clinic that asks the patient to compress the list, or that frames the questions themselves as a sign of insufficient trust, is providing a useful signal of its own.
What if the clinic answers most of the ten well, but resists one or two?
Patterns matter more than perfection. A clinic that answers eight of the ten with documentary clarity but resists one — typically the regulatory registration question or the categorical outcome claims question — is offering a partial reassurance, and the cosmopolitan reader is well advised to slow the appointment rather than accept the gap. A second consultation, ideally with a different clinic in the same Gangnam register, often clarifies whether the resistance is structural or merely procedural; one returns to the original clinic, where appropriate, with the comparison in hand.
Are these questions specific to stem cell therapy, or do they apply to other treatments?
The structural ten — operator identity, evidence base, risk profile, pricing, consent advance review, timeline, aftercare, regulatory registration, patient rights — apply broadly to any aesthetic or regenerative protocol one is considering in Korea. Question one, on cell preparation, is specific to cell-based protocols; for other treatments, it is replaced by an equivalent procedural-identity question — the device generation, the active ingredient, the surgical technique. The editorial discipline of the list, however, is portable across the category.
Is it appropriate to ask the consulting physician these questions, or only the coordinator?
Both, at different phases. The coordinator handles the first-pass logistical and procedural items — cost itemisation, consent in advance, registration verification, aftercare contact — and will route the medically substantive questions to the consulting physician. The evidence base, the risk profile, the timeline, and the cell-preparation specifics belong in the physician consultation itself. A clinic where the coordinator answers all ten without physician involvement is a clinic where the physician's role has been compressed in a way that should give the careful reader pause.
Should I ask for the answers in writing, or is verbal confirmation sufficient?
The medically substantive answers — cell preparation, risk profile, timeline, aftercare protocol — should travel home with the patient on letterhead or in a clinic-issued document; the regulatory and structural answers — licence number, registration number, itemised pricing, patient rights — likewise belong in writing. Verbal answers are appropriate during the consultation itself, but the documentary version is what one reviews on the hotel terrace later that evening, and what one's GP at home can refer to in the weeks after. A clinic that provides written answers without prompting is reading the standard of care correctly.
How long should I expect the consultation to take if I work through all ten questions?
A consultation that addresses the ten properly typically runs between sixty and ninety minutes, sometimes split across two sessions on different days where the cell-preparation report or the itemised quote is being prepared between visits. A consultation that promises to cover the same ground in twenty minutes is operating at the wrong pace. The Hong Kong reader, trained on Causeway Bay's faster cadence, often finds the slower pacing initially unfamiliar; by the second consultation, the rhythm reads as exactly the dose the protocol's stakes deserve.
What if I have already booked, but have not yet asked the ten questions?
One asks them now, before the procedure date, by email or by an additional pre-procedure consultation. The Korean medical framework, as KHIDI's patient-facing material sets out, does not penalise a patient for asking substantive questions late — the right to withdraw or to pause consent is held throughout the pre-procedure window. A clinic that welcomes the supplementary conversation is the clinic one wants to be entering the procedure room with; a clinic that frames the late questions as administratively inconvenient is one whose pacing has been organised around the wrong centre of gravity.